Search results for "THROMBOEMBOLISM"

showing 10 items of 208 documents

Risk factors, atrial fibrillation and thromboembolic events.

2008

AIM: The aim of this study was to evaluate the relation between risk factors for atrial fibrillation (AF) and thromboembolic complications. METHODS: We studied 480 patients (mean age: 71.2+/-11.6 years): 240 with paroxysmal AF, 240 with permanent AF. The association between AF and the presence of risk factors, cardiac and systemic disease was observed and the correlation with the occurrence of complications analyzed. RESULTS: Patients with AF had a high prevalence of the following conditions: hypertension, hypertensive heart disease (HHD), coronary artery disease, hyperthyroidism. Thromboembolism was observed in 26.6% of the patients. A correlation between the occurrence of a thromboembolic…

AdultAged 80 and overMaleHypercholesterolemiaSmokingFibrinogenMiddle Agedatrial fibrillation risk factorsCohort StudiesDiabetes ComplicationsYoung AdultRisk FactorsThromboembolismAtrial FibrillationHypertensionHumansFemaleObesityAgedInternational angiology : a journal of the International Union of Angiology
researchProduct

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

2021

Background Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19. Methods In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge. Results Of 1529 COVID-19 patients discharge…

AdultMaleARDSmedicine.medical_specialtyTime FactorsDeep veinIran030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsFull Length ArticleInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionThromboprophylaxisStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryIncidenceIncidence (epidemiology)COVID-19Venous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisPatient DischargePulmonary embolismHospitalizationmedicine.anatomical_structure030220 oncology & carcinogenesisHeart failureFemaleCohort studyPulmonary EmbolismbusinessThrombosis Research
researchProduct

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

2016

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicineVenous thrombosisLow Molecular Weight HeparinHumansMedicineacute leukemiacardiovascular diseaseseducationAgedAged 80 and overVenous ThrombosisAcute leukemiaeducation.field_of_studyAcute leukemiaChemotherapyLeukemiabusiness.industrylow molecular weight heparinIncidenceIncidence (epidemiology)Disease ManagementVenous ThromboembolismHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryVenous thrombosisOncology030220 oncology & carcinogenesisAcute DiseaseFemaleacute leukemia; low molecular weight heparin; Venous thrombosisbusinessSettore MED/15 - Malattie del SangueVenous thromboembolismLeukemia & Lymphoma
researchProduct

Hemodynamic Effects of Nonionic Contrast Bolus Injection and Oxygen Inhalation During Pulmonary Angiography in Patients With Chronic Major-Vessel Thr…

1996

Background Pulmonary angiography is the gold standard for the diagnosis of chronic thromboembolic pulmonary hypertension; however, major complications have been reported. This study evaluates the hemodynamic effects of direct pulmonary nonionic contrast bolus injection and oxygen inhalation in patients with chronic thromboembolic pulmonary hypertension. Methods and Results In 33 patients, hemodynamic parameters were measured after oxygen inhalation and during bolus injection of nonionic contrast medium in a control group (group 1, n=11), in a group of patients with moderately severe pulmonary hypertension (group 2, n=9), and in a group with severe pulmonary hypertension (group 3, n=13). Ox…

AdultMalePulmonary CirculationHypertension PulmonaryContrast MediaInjectionsPulmonary heart diseaseThromboembolismPhysiology (medical)medicine.arteryAdministration InhalationmedicinePulmonary angiographyHumansAgedmedicine.diagnostic_testInhalationbusiness.industryRespiratory diseaseHemodynamicsAngiography Digital SubtractionMiddle Agedmedicine.diseasePulmonary hypertensionOxygenmedicine.anatomical_structureAnesthesiaAngiographyPulmonary arteryVascular resistanceFemaleCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer

2008

Limited information exists on the incidence of symptomatic venous thromboembolism (vTE) in patients undergoing chest surgery for lung cancer. Several factors increase the thromboembolic risk in patients undergoing surgery for lung cancer: the intrinsic procoagulant effect of cancer,extensive surgical intervention, dependent limb position in the operating room, and vessel injury consequent to the operation. Furthermore,these patients might be especially vulnerable to pulmonary embolism (PE) because of the loss of lung tissue and the presence of chronic obstructive pulmonary disease and cardiovascular diseases caused by smoking.t Older studies found a very high incidence of thromboembolic eve…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSeverity of Illness Indexvenous thromboembolism thoracotomySettore MED/15 - Malattie Del SangueCohort StudiesAge DistributionPostoperative ComplicationsRisk FactorsmedicineHumansMulticenter Studies as TopicThoracotomySex DistributionLung cancerPneumonectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overOntariobusiness.industryVascular diseaseIncidence (epidemiology)IncidenceRespiratory diseaseCancerAnticoagulantsRetrospective cohort studyVenous ThromboembolismMiddle Agedmedicine.diseasePrognosisSurvival AnalysisSurgeryVenous thrombosisItalyThoracotomyFemaleSurgerybusinessPulmonary EmbolismCardiology and Cardiovascular MedicineThe Journal of Thoracic and Cardiovascular Surgery
researchProduct

Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.

2008

Objective Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and patients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events. There are no data on thromboembolic event risk for these patients. Methods We assessed the current practice patterns in the management of patients with mechanical heart valves with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were reviewed. Patients with a history of stable, therapeutic a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classLow molecular weight heparinProsthesis DesignRisk AssessmentSettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultThromboembolismAntithromboticmedicineHumansInternational Normalized RatioINR anticoagulant mechanical heart valvesAgedRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyMiddle AgedVitamin K antagonistConfidence intervalSurgeryHeart Valve ProsthesisFemaleSurgeryRisk assessmentbusinessCardiology and Cardiovascular MedicineCohort study
researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins

2008

Introduction. Superficial venous thrombosis (SVT) has been considered for a long time a limited clinical condition with a low importance, but this approach has changed in recent years, when several studies demonstrated spreading to deep veins occurring from 7.3 to 44%, with high prevalence of pulmonary embolism . Materials and Methods. To evaluate the prevalence of genetic risk factors for VTE in patients suffering from SVT on both normal and varicose vein, and to evaluate their role on spreading to deep veins, we studied 107 consecutive outpatients with symptomatic SVT. Ultrasound examination was performed, and the presence of FV Leiden, Prothrombin G20210A mutation, MTHFR C677T mutation w…

AdultMalemedicine.medical_specialtyAdolescentDeep veinThrombophiliaGastroenterologyVeinsCohort StudiesVaricose VeinsYoung AdultRisk FactorsInternal medicineVaricose veinsmedicinePrevalenceHumansGenetic Predisposition to DiseaseMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisColor-duplex-Ultrasonography Genetic Risk Factors Superficial Venous Thrombosis Venous ThromboembolismVascular diseasebusiness.industryFactor VHematologyMiddle Agedmedicine.diseaseThrombosisSettore MED/11 - Malattie Dell'Apparato CardiovascolarePulmonary embolismVenous thrombosismedicine.anatomical_structureEmbolismMutationFemaleProthrombinRadiologymedicine.symptombusinessPhlebitisPulmonary Embolism
researchProduct